We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 25, 2022

Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy

Journal of the National Cancer Institute

 

Additional Info

Journal of the National Cancer Institute
Impact of age on clinical outcomes and efficacy of adjuvant dual anti-HER2 targeted therapy
J. Natl. Cancer Inst 2022 May 05;[EPub Ahead of Print], M Lambertini, S Fielding, S Loibl, W Janni, E Clark, MA Franzoi, D Fumagalli, C Caballero, L Arecco, S Salomoni, NF Ponde, F Poggio, HJ Kim, C Villarreal-Garza, O Pagani, S Paluch-Shimon, A Ballestrero, L Del Mastro, M Piccart, J Bines, AH Partridge, E de Azambuja

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading